Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

preCARDIA Enrolls First Patient in Early Feasibility Study

August 15, 2019

News Industry News

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

July 23, 2019

News Industry News

Edwards' Acumen Hypotension Prediction Index Launches In The U.S.

March 19, 2018

News Industry News

NanoCor Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) for Carfostin®

April 20, 2016

News Industry News

Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments

January 03, 2016

News Industry News

scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure

November 03, 2015

News Industry News

BioControl Medical Completes Enrollment in the INOVATE-HF Study of the CardioFit® System to Treat Heart Failure

August 27, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

Advertisement

preCARDIA Enrolls First Patient in Early Feasibility Study

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

Edwards' Acumen Hypotension Prediction Index Launches In The U.S.

NanoCor Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) for Carfostin®

Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments

scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure

BioControl Medical Completes Enrollment in the INOVATE-HF Study of the CardioFit® System to Treat Heart Failure

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content